Integra Lifesciences (IART) Stock Rating Lowered by Zacks Investment Research
According to Zacks, “Integra LifeSciences exited the first quarter of 2019 on a mixed note with better-than-expected earnings and a revenue miss. However, organic revenue growth was encouraging and was in line with the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in mid-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.”
Several other equities research analysts have also recently weighed in on the company. Morgan Stanley set a $57.00 price objective on Integra Lifesciences and gave the company a “hold” rating in a research report on Friday, February 22nd. Cantor Fitzgerald restated a “hold” rating and issued a $50.00 target price on shares of Integra Lifesciences in a research note on Thursday, February 21st. JMP Securities restated a “buy” rating and issued a $62.00 target price on shares of Integra Lifesciences in a research note on Wednesday, February 27th. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research note on Tuesday, March 19th. Finally, BidaskClub upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $59.42.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.04. Integra Lifesciences had a return on equity of 15.60% and a net margin of 5.60%. The company had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. During the same period in the prior year, the business earned $0.58 earnings per share. Integra Lifesciences’s revenue for the quarter was up .7% compared to the same quarter last year. Equities analysts predict that Integra Lifesciences will post 2.7 EPS for the current year.
In related news, Director Christian S. Schade sold 15,658 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lisa Evoli sold 1,291 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $55.90, for a total value of $72,166.90. Following the completion of the transaction, the insider now owns 4,968 shares of the company’s stock, valued at $277,711.20. The disclosure for this sale can be found here. Insiders sold 47,077 shares of company stock valued at $2,568,469 over the last 90 days. 4.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Jefferies Group LLC bought a new position in Integra Lifesciences during the first quarter worth about $994,000. ExodusPoint Capital Management LP acquired a new position in shares of Integra Lifesciences during the 1st quarter worth $600,000. ArrowMark Colorado Holdings LLC raised its holdings in shares of Integra Lifesciences by 10.1% during the 1st quarter. ArrowMark Colorado Holdings LLC now owns 738,863 shares of the life sciences company’s stock worth $41,169,000 after buying an additional 67,660 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth $439,000. Finally, Wellington Management Group LLP raised its holdings in shares of Integra Lifesciences by 3.5% during the 1st quarter. Wellington Management Group LLP now owns 4,457,745 shares of the life sciences company’s stock worth $248,385,000 after buying an additional 149,640 shares in the last quarter. Hedge funds and other institutional investors own 84.29% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: How to track put option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.